This is a type of cancer found in elderly patients
Not Applicable
- Conditions
- Health Condition 1: C851- Unspecified B-cell lymphoma
- Registration Number
- CTRI/2022/09/045751
- Lead Sponsor
- Investigator initiated trial
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
Inclusion Criteria
1. Newly diagnosed cases of Diffuse Large B cell Lymphoma
2. Age more than or equal to 60 years.
3. Patients who provide written informed consent
Exclusion Criteria
1. None
The patients found to meet all inclusion criteria of the study will thereafter be administered the informed
consent process
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Proportion of participants achieving complete response and partial response in clinical trial eligible <br/ ><br>and clinical trial ineligible cohort receiving RCHOP, will be measured.Timepoint: 6 months
- Secondary Outcome Measures
Name Time Method Survival analysis will be calculated from the date of enrolment till the end of 1 year, data will be <br/ ><br>censored in case the patient is lost to follow-up. <br/ ><br>Timepoint: after completion of one year treatment;Comparison of dose modifications in all the treatment cohortsTimepoint: during the treatment;Comparison of grade III and grade IV toxicities in all treatment cohorts:Timepoint: during the treatment;Proportion of patients achieving complete and partial response in clinical trial ineligible and in <br/ ><br>clinical trial eligible cohort receiving RCEOP regimen.Timepoint: after completion of treatment;Proportion of patients in the clinical trial eligible cohort.Timepoint: after the enrollment